Royalty Pharma Declares Third Quarter 2022 Dividend
The board of directors of Royalty Pharma (RPRX) has declared a third-quarter dividend of $0.19 per Class A ordinary share. This dividend will be paid on September 15, 2022, to shareholders on record by the close of business on August 19, 2022. Royalty Pharma, a leader in biopharmaceutical royalties, supports innovation across the industry and has a portfolio that includes royalties on approximately 35 commercial products, enhancing shareholder value.
- Declaration of a third-quarter dividend of $0.19 enhances shareholder returns.
- Royalty Pharma's diverse portfolio includes royalties on approximately 35 commercial products.
- None.
NEW YORK, July 15, 2022 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the third quarter of 2022 of
The dividend will be paid on September 15, 2022, to shareholders of record at the close of business on August 19, 2022.
About Royalty Pharma
Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and non-for-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry’s leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly - directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators. Royalty Pharma’s current portfolio includes royalties on around 35 commercial products, including AbbVie and Johnson & Johnson’s Imbruvica, Johnson & Johnson’s Tremfya, Astellas’ and Pfizer’s Xtandi, Biogen’s Tysabri, Gilead’s Trodelvy, Novartis’ Promacta, Vertex’s Kalydeco, Orkambi, Symdeko and Trikafta, and 10 development-stage therapies. For more information, visit www.royaltypharma.com.
Royalty Pharma Investor Relations and Communications
+1 (212) 883-6772
ir@royaltypharma.com
FAQ
What is the dividend amount declared by Royalty Pharma for the third quarter of 2022?
When will Royalty Pharma's third-quarter dividend be paid?
What is the record date for Royalty Pharma's third-quarter dividend?
How many commercial products does Royalty Pharma have in its portfolio?
